Class information for: |
Basic class information |
Class id | #P | Avg. number of references |
Database coverage of references |
---|---|---|---|
21324 | 424 | 47.9 | 94% |
Hierarchy of classes |
The table includes all classes above and classes immediately below the current class. |
Cluster id | Level | Cluster label | #P |
---|---|---|---|
0 | 4 | BIOCHEMISTRY & MOLECULAR BIOLOGY//CELL BIOLOGY//ONCOLOGY | 4064930 |
10 | 3 | IMMUNOLOGY//JOURNAL OF IMMUNOLOGY//IMMUNOL | 134299 |
854 | 2 | CD40//BAFF//CD40 LIGAND | 11643 |
21324 | 1 | TWEAK//FN14//STWEAK | 424 |
Terms with highest relevance score |
rank | Term | termType | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|---|
1 | TWEAK | authKW | 7227275 | 31% | 77% | 131 |
2 | FN14 | authKW | 5562150 | 21% | 89% | 87 |
3 | STWEAK | authKW | 1440329 | 5% | 100% | 20 |
4 | TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS | authKW | 610015 | 3% | 71% | 12 |
5 | FIBROBLAST GROWTH FACTOR INDUCIBLE 14 | authKW | 504115 | 2% | 100% | 7 |
6 | FIBROBLAST GROWTH FACTOR INDUCIBLE 14 FN14 | authKW | 432099 | 1% | 100% | 6 |
7 | TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS TWEAK | authKW | 360082 | 1% | 100% | 5 |
8 | TWEAKR | authKW | 360082 | 1% | 100% | 5 |
9 | UNIT DETECT TREATMENT ATHEROTHROMBOT DIS | address | 216049 | 1% | 100% | 3 |
10 | TNF LIKE WEAK INDUCER OF APOPTOSIS | authKW | 162036 | 1% | 75% | 3 |
Web of Science journal categories |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | Immunology | 855 | 23% | 0% | 96 |
2 | Urology & Nephrology | 499 | 11% | 0% | 45 |
3 | Cell Biology | 438 | 18% | 0% | 76 |
4 | Biochemistry & Molecular Biology | 226 | 23% | 0% | 96 |
5 | Oncology | 139 | 11% | 0% | 48 |
6 | Medicine, Research & Experimental | 117 | 7% | 0% | 31 |
7 | Rheumatology | 99 | 3% | 0% | 13 |
8 | Peripheral Vascular Diseases | 78 | 5% | 0% | 20 |
9 | Pathology | 59 | 4% | 0% | 17 |
10 | Cardiac & Cardiovascular System | 52 | 6% | 0% | 24 |
Address terms |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | UNIT DETECT TREATMENT ATHEROTHROMBOT DIS | 216049 | 1% | 100% | 3 |
2 | VASC INFLAMMATORY DIS | 149709 | 6% | 9% | 24 |
3 | OTOLARYNGOL DIS GRP HJ23 | 144033 | 0% | 100% | 2 |
4 | VASC EACH | 144033 | 0% | 100% | 2 |
5 | PULM PHARMACOTHER Y | 108022 | 1% | 50% | 3 |
6 | EXPLORATORY SCI | 99706 | 1% | 23% | 6 |
7 | BIOMED NETWORK DIABET ASSOCIATED METAB | 96021 | 0% | 67% | 2 |
8 | SKELETAL MUSCLE PHYSIOL NEUROBIOL | 96021 | 0% | 67% | 2 |
9 | ANETESIOL REANIMAT | 72016 | 0% | 100% | 1 |
10 | AUTOIMMUN DRUG DISCOVERY | 72016 | 0% | 100% | 1 |
Journals |
Rank | Term | Chi square | Shr. of publ. in class containing term |
Class's shr. of term's tot. occurrences |
#P with term in class |
---|---|---|---|---|---|
1 | FRONTIERS IN IMMUNOLOGY | 3556 | 3% | 0% | 12 |
2 | CYTOKINE | 2332 | 3% | 0% | 12 |
3 | MOLECULAR CANCER RESEARCH | 956 | 1% | 0% | 5 |
4 | BMC NEPHROLOGY | 891 | 1% | 0% | 4 |
5 | CYTOKINE & GROWTH FACTOR REVIEWS | 804 | 1% | 0% | 3 |
6 | CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 640 | 1% | 0% | 5 |
7 | EUROPEAN JOURNAL OF INFLAMMATION | 578 | 0% | 0% | 2 |
8 | FRONTIERS IN BIOSCIENCE-LANDMARK | 495 | 1% | 0% | 5 |
9 | JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY | 475 | 2% | 0% | 7 |
10 | ARTHRITIS RESEARCH | 394 | 0% | 1% | 1 |
Author Key Words |
Core articles |
The table includes core articles in the class. The following variables is taken into account for the relevance score of an article in a cluster c: (1) Number of references referring to publications in the class. (2) Share of total number of active references referring to publications in the class. (3) Age of the article. New articles get higher score than old articles. (4) Citation rate, normalized to year. |
Rank | Reference | # ref. in cl. |
Shr. of ref. in cl. |
Citations |
---|---|---|---|---|
1 | WAJANT, H , (2013) THE TWEAK-FN14 SYSTEM AS A POTENTIAL DRUG TARGET.BRITISH JOURNAL OF PHARMACOLOGY. VOL. 170. ISSUE 4. P. 748-764 | 101 | 82% | 20 |
2 | CHENG, E , ARMSTRONG, CL , GALISTEO, R , WINKLES, JA , (2013) TWEAK/FN14 AXIS-TARGETED THERAPEUTICS: MOVING BASIC SCIENCE DISCOVERIES TO THE CLINIC.FRONTIERS IN IMMUNOLOGY. VOL. 4. ISSUE . P. - | 88 | 68% | 11 |
3 | SANZ, AB , SANCHEZ-NINO, MD , ORTIZ, A , (2011) TWEAK, A MULTIFUNCTIONAL CYTOKINE IN KIDNEY INJURY.KIDNEY INTERNATIONAL. VOL. 80. ISSUE 7. P. 708 -718 | 81 | 76% | 25 |
4 | BURKLY, LC , MICHAELSON, JS , ZHENG, TS , (2011) TWEAK/FN14 PATHWAY: AN IMMUNOLOGICAL SWITCH FOR SHAPING TISSUE RESPONSES.IMMUNOLOGICAL REVIEWS. VOL. 244. ISSUE . P. 99-114 | 67 | 78% | 72 |
5 | WINKLES, JA , (2008) THE TWEAK - FN14 CYTOKINE-RECEPTOR AXIS: DISCOVERY, BIOLOGY AND THERAPEUTIC TARGETING.NATURE REVIEWS DRUG DISCOVERY. VOL. 7. ISSUE 5. P. 411 -425 | 74 | 59% | 254 |
6 | SANZ, AB , IZQUIERDO, MC , SANCHEZ-NINO, MD , UCERO, AC , EGIDO, J , RUIZ-ORTEGA, M , RAMOS, AM , PUTTERMAN, C , ORTIZ, A , (2014) TWEAK AND THE PROGRESSION OF RENAL DISEASE: CLINICAL TRANSLATION.NEPHROLOGY DIALYSIS TRANSPLANTATION. VOL. 29. ISSUE . P. I54-I62 | 55 | 80% | 13 |
7 | ARMSTRONG, CL , GALISTEO, R , BROWN, SAN , WINKLES, JA , (2016) TWEAK ACTIVATION OF THE NON-CANONICAL NF-KAPPA B SIGNALING PATHWAY DIFFERENTIALLY REGULATES MELANOMA AND PROSTATE CANCER CELL INVASION.ONCOTARGET. VOL. 7. ISSUE 49. P. 81474 -81492 | 58 | 81% | 0 |
8 | DOHI, T , BURKLY, LC , (2012) THE TWEAK/FN14 PATHWAY AS AN AGGRAVATING AND PERPETUATING FACTOR IN INFLAMMATORY DISEASES; FOCUS ON INFLAMMATORY BOWEL DISEASES.JOURNAL OF LEUKOCYTE BIOLOGY. VOL. 92. ISSUE 2. P. 265 -279 | 67 | 63% | 26 |
9 | SHARIF, MN , CAMPANHOLLE, G , NAGIEC, EE , WANG, J , SYED, J , O'NEIL, SP , ZHAN, YT , BRENNEMAN, K , HOMER, B , NEUBERT, H , ET AL (2016) SOLUBLE FN14 IS DETECTED AND ELEVATED IN MOUSE AND HUMAN KIDNEY DISEASE.PLOS ONE. VOL. 11. ISSUE 5. P. - | 51 | 76% | 0 |
10 | ORTIZ, A , SANZ, AB , GARCIA, BM , MORENO, JA , NINO, MDS , MARTIN-VENTURA, JL , EGIDO, J , BLANCO-COLIO, LM , (2009) CONSIDERING TWEAK AS A TARGET FOR THERAPY IN RENAL AND VASCULAR INJURY.CYTOKINE & GROWTH FACTOR REVIEWS. VOL. 20. ISSUE 3. P. 251-258 | 58 | 72% | 27 |
Classes with closest relation at Level 1 |
Rank | Class id | link |
---|---|---|
1 | 22230 | DCR3//DECOY RECEPTOR 3//TL1A |
2 | 10318 | HAPTOGLOBIN//CD163//HAPTOGLOBIN PHENOTYPE |
3 | 8273 | BAFF//APRIL//BLYS |
4 | 8433 | MURF1//ATROGIN 1//MUSCLE WASTING |
5 | 24952 | PHARMACEUT PROTE//TNFR2//TNF DEFICIENCY |
6 | 17952 | TRAF4//TRAF6//TRAF2 |
7 | 36251 | CELL RECOGNIT PONSE//I KAPPA B ZETA//I KAPPA B XI |
8 | 28577 | CXCL16//CXCR6//SR PSOX |
9 | 7566 | GLOMERULONEPHRITIS//INFLAMMATORY DIS//NEPHROTOXIC NEPHRITIS |
10 | 10004 | NECROPTOSIS//RIP3//RIP1 |